Novel Therapies for the Treatment of Cardiovascular Disease.
Med Clin North Am
; 108(5): 953-964, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-39084843
ABSTRACT
Over the last decade, randomized clinical trials of several pharmacologic agents have demonstrated a reduction in cardiovascular mortality and other important secondary outcomes. Angiotensin-Neprilysin Inhibitors and Sodium-Glucose Co-transporter 2 inhibitors have now become pillars in the treatment of heart failure. Ivabradine is a negative chronotropic agent used as an adjunctive therapy in patients with heart failure. Two new hypertension therapies, zilebresiran and aprocitentan, are currently in investigational stages. Finally, mavacamten has emerged as a pharmacologic treatment for hypertrophic obstructive cardiomyopathy. Practitioners must be familiar with the indications and side effects of newer therapies as they are now frequently prescribed.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Cardiovascular Diseases
Limits:
Humans
Language:
En
Journal:
Med Clin North Am
Year:
2024
Document type:
Article
Country of publication: